198494-75-6

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-BromoBenzyl)-2,2-diMethyl-1,3-dioxane-4,6-dione is used as an intermediate in the production of pharmaceuticals for its ability to facilitate the synthesis of complex molecules. Its unique structure and reactivity contribute to the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(4-BromoBenzyl)-2,2-diMethyl-1,3-dioxane-4,6-dione serves as an intermediate, playing a crucial role in the synthesis of various agrochemical products, potentially enhancing crop protection and yield.
Used in Materials Science:
5-(4-BromoBenzyl)-2,2-diMethyl-1,3-dioxane-4,6-dione is utilized in materials science as a component in the development of new materials, leveraging its structural properties to improve material performance.
Used in Organic Synthesis:
As a key building block in organic synthesis, 5-(4-BromoBenzyl)-2,2-diMethyl-1,3-dioxane-4,6-dione is used for the creation of a wide array of organic compounds, contributing to the advancement of chemical research and product development.
Used in Anti-inflammatory and Antioxidant Applications:
Due to its anti-inflammatory and antioxidant properties, 5-(4-BromoBenzyl)-2,2-diMethyl-1,3-dioxane-4,6-dione is of interest for potential pharmaceutical applications, where it may be developed into treatments for conditions that involve inflammation or oxidative stress.

Upstream product

• 15795-59-2 5-(4-bromobenzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 95-54-5 1,2-diamino-benzene 
• 2033-24-1 cycl-isopropylidene malonate 

Downstream Products

• 80793-25-5 3-(4-bromophenyl)propanal 
• 1167473-13-3 2-(4-bromobenzyl)malonic acid ethyl ester methyl ester 
• 15795-59-2 5-(4-bromobenzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 196394-93-1 methyl 2-[(4-bromophenyl)methyl]prop-2-enoate 
• 860256-21-9 2-(4-bromobenzyl)acrylic acid 
• 1146212-16-9 2-(4-bromobenzyl)-3-hydroxy-propionic acid 
• 14548-39-1 6-bromoindan-1-one 
• 1643-30-7 3-(4-bromophenyl)propionic acid 

Relevant academic research and scientific papers

Challenges in the Development of a Thiol-Based Broad-Spectrum Inhibitor for Metallo-β-Lactamases

Pathogens, expressing metallo-β-lactamases (MBLs), become resistant against most β-lactam antibiotics. Besides the dragging search for new antibiotics, development of MBL inhibitors would be an alternative weapon against resistant bacterial pathogens. Inhibition of resistance enzymes could restore the antibacterial activity of β-lactams. Various approaches to MBL inhibitors are described; among others, the promising motif of a zinc coordinating thiol moiety is very popular. Nevertheless, since the first report of a thiol-based MBL inhibitor (thiomandelic acid) in 2001, no steps in development of thiol based MBL inhibitors were reported that go beyond clinical isolate testing. In this study, we report on the synthesis and biochemical characterization of thiol-based MBL inhibitors and highlight the challenges behind the development of thiol-based compounds, which exhibit good in vitro activity toward a broad spectrum of MBLs, selectivity against human off-targets, and reasonable activity against clinical isolates.

Synthesis of 2-aryl-1H-benzimidazoles and 2-aryl-1H-perimidines using arylidene Meldrum’s acid as a source of the aryl group and oxidant

Arylidene Meldrum’s acid is employed as a source of the aryl group and oxidant for the synthesis of 2-aryl-1H–benzimidazoles by a condensation reaction with 1,2-phenylenediamine in refluxing ethanol with good to high yields. Arylidene Meldrum’s acids were

2,3-BENZODIAZEPINES

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

2, 3-benzodiazepins

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

Lewis base-promoted hydrosilylation of cyclic malonates: Synthesis of β-substituted aldehydes and γ-substituted amines

The Lewis base-promoted hydrosilylation of cyclic malonates provides a convenient synthesis of β-substituted aldehydes. No over-reduction to the primary alcohol is observed as the aldehyde functionality is protected until a subsequent hydrolysis step. The